{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497697,"version":"4.8.0"},"reference-count":31,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) followed by Isa-Rd (N=265) versus VRd followed by Rd (N=181) in newly diagnosed transplant-ineligible MM (Ti NDMM) patients using the simplified International Myeloma Working Group (sIMWG) frailty score. Although patients aged &gt;80 years were excluded, there was no exclusion for patients meeting frailty criteria. All patients received standard VRd\/Rd dosing; Isa-VRd patients received intravenous Isa (cycle 1, 10 mg\/kg once weekly; cycles 2-17, once every 2 weeks; subsequent cycles, once every 4 weeks). Patients with a frailty score of 0\/1 were considered nonfrail; scores \u22652 were frail. Using this scoring, 26.7% of patients were frail (26.0% Isa-VRd; 27.6% VRd), and 72.0% non-frail (72.8% Isa-VRd; 70.7% VRd). After a median follow-up of 59.7 months, Isa-VRd significantly improved progression-free survival versus VRd in frail patients (hazard ratio [HR] =0.518; 95% confidence interval [CI]: 0.294-0.912; P=0.0227) and non-frail patients (HR=0.615; 95% CI: 0.419-0.903; P=0.0131). Significantly more frail patients receiving Isa-VRd than VRd achieved minimal residual disease negativity and complete response (odds ratio=3.459; 95% CI: 1.495-8.006; P=0.0030 at 10-5 by next-generation sequencing). Rates of treatment-emergent adverse events leading to definitive discontinuation were similar between both arms regardless of frailty status. This post hoc subgroup analysis of the IMROZ trial demonstrated that Isa-VRd is an effective option with a manageable safety profile for frail patients with Ti NDMM (clinicaltrials gov. Identifier: NCT03319667).<\/jats:p>","DOI":"10.3324\/haematol.2024.287200","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:20:19Z","timestamp":1742444419000},"page":"2139-2150","source":"Crossref","is-referenced-by-count":14,"title":["Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial"],"prefix":"10.3324","volume":"110","author":[{"given":"Salomon","family":"Manier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier P.","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Tron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tekle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Br\u00e9geault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea T.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"78922","doi-asserted-by":"crossref","unstructured":"Martin TG, Corzo K, Chiron M. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019; 8(12):1522.","DOI":"10.3390\/cells8121522"},{"key":"78923","doi-asserted-by":"crossref","unstructured":"Deckert J, Wetzel MC, Bartle LM. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014; 20(17):4574-4583.","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"78924","doi-asserted-by":"crossref","unstructured":"Moreno L, Perez C, Zabaleta A. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019; 25(10):3176-3187.","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"78925","doi-asserted-by":"crossref","unstructured":"Zhu C, Song Z, Wang A. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020; 11:1771.","DOI":"10.3389\/fimmu.2020.01771"},{"key":"78926","doi-asserted-by":"crossref","unstructured":"Attal M, Richardson PG, Rajkumar SV. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394(10214):2096-2107.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"78927","doi-asserted-by":"crossref","unstructured":"Martin T, Dimopoulos MA, Mikhael J. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J. 2023; 13(1):72.","DOI":"10.1038\/s41408-023-00797-8"},{"key":"78928","doi-asserted-by":"crossref","unstructured":"Richardson PG, Perrot A, San-Miguel J. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022; 23(3):416-427.","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"78929","doi-asserted-by":"crossref","unstructured":"Moreau P, Dimopoulos MA, Mikhael J. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021; 397(10292):2361-2371.","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"78930","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Leleu XP. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024; 391(17):1597-1609.","DOI":"10.1056\/NEJMoa2400712"},{"key":"78931","unstructured":"FDA approves isatuximab-irfc with bortezomib lenalidomide and dexamethasone for newly diagnosed multiple myeloma. 2024."},{"key":"78932","unstructured":"Sanofi. Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma. 2024."},{"key":"78933","unstructured":"Sanofi: ANVISA aprova SARCLISA\u00ae em combina\u00e7\u00e3o ao VRd para o tratamento de pacientes com mieloma m\u00faltiplo rec\u00e9m-diagnosticados. 2024."},{"key":"78934","doi-asserted-by":"crossref","unstructured":"Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A. Difficult-to-treat patients with relapsed\/refractory multiple myeloma: a review of clinical trial results. EJHaem. 2023; 4(4):1117-1131.","DOI":"10.1002\/jha2.743"},{"key":"78935","doi-asserted-by":"crossref","unstructured":"Grant SJ, Freeman CL, Rosko AE. Treatment of older adult or frail patients with multiple myeloma. Hematology Am Soc Hematol Educ Program. 2021; 2021(1):46-54.","DOI":"10.1182\/hematology.2021000231"},{"key":"78936","doi-asserted-by":"crossref","unstructured":"Miller HL, Sharpley FA. Frail multiple myeloma patients deserve more than just a score. Hematol Rep. 2023; 15(1):151-156.","DOI":"10.3390\/hematolrep15010015"},{"key":"78937","doi-asserted-by":"crossref","unstructured":"Mian H, McCurdy A, Giri S. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood Cancer J. 2023; 13(1):6.","DOI":"10.1038\/s41408-022-00779-2"},{"key":"78938","doi-asserted-by":"crossref","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014; 32(6):587-600.","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"78939","doi-asserted-by":"crossref","unstructured":"Haider I, Leong DP, Louzada M. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leuk Lymphoma. 2024; 65(8):1167-1174.","DOI":"10.1080\/10428194.2024.2340052"},{"key":"78940","doi-asserted-by":"crossref","unstructured":"Facon T, Cook G, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022; 36(4):1066-1077.","DOI":"10.1038\/s41375-021-01488-8"},{"key":"78941","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Meuleman N. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020; 34(1):224-233.","DOI":"10.1038\/s41375-019-0539-0"},{"key":"78942","doi-asserted-by":"crossref","unstructured":"Mateos MV, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021; 21(11):785-798.","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"78943","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"78944","doi-asserted-by":"crossref","unstructured":"Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl. 2007; 13(11):1515-1520.","DOI":"10.1002\/lt.21172"},{"key":"78945","doi-asserted-by":"crossref","unstructured":"Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-655.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"78946","doi-asserted-by":"crossref","unstructured":"Schjesvold F, Bringhen S, P GR. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol. 2021; 96(11):E423-E427.","DOI":"10.1002\/ajh.26319"},{"key":"78947","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Facon T, Hungria V. OA - 63: Daratumumab + bortezomib\/lenalidomide\/dexamethasone in patients With transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: results of the phase 3 CEPHEUS study. Presented at: International Myeloma Society 2024 annual meeting 2024.","DOI":"10.1016\/S2152-2650(24)02344-9"},{"key":"78948","doi-asserted-by":"crossref","unstructured":"Zweegman S, Usmani SZ, Chastain K. Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: a multicenter, randomized, phase III study (CEPHEUS). Journal of Clinical Oncology. 2019; 37(Suppl 15):TPS8056.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056"},{"key":"78949","doi-asserted-by":"crossref","unstructured":"Bonello F, Grasso M, D\u2019Agostino M. The role of monoclonal antibodies in the first-line treatment of transplant-ineligible patients with newly diagnosed multiple myeloma. Pharmaceuticals (Basel). 2020; 14(1):20.","DOI":"10.3390\/ph14010020"},{"key":"78950","doi-asserted-by":"crossref","unstructured":"Leleu X, Hulin C, Lambert J. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024; 30(8):2235-2241.","DOI":"10.1038\/s41591-024-03050-2"},{"key":"78951","doi-asserted-by":"crossref","unstructured":"Mohty M, Facon T, Malard F, Harousseau JL. A roadmap towards improving outcomes in multiple myeloma. Blood Cancer J. 2024; 14(1):135.","DOI":"10.1038\/s41408-024-01115-6"},{"key":"78952","doi-asserted-by":"crossref","unstructured":"Li Y, Zhao S, Xu J. Selection determines therapeutic effects: a retrospective analysis of the application of different frailty tools in elderly patients with multiple myeloma. Discov Oncol. 2024; 15(1):546.","DOI":"10.1007\/s12672-024-01305-5"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11994\/78195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11994\/78741","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11994\/78195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:24Z","timestamp":1794046104000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287200","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}